* Certriad gets complete response letter from U.S. agency
* Drug combines Astra’s Crestor and Abbott’s TriLipix
(Adds detail on drug, background)
LONDON, March 30 (Reuters) - A experimental heart drug from AstraZeneca AZN.L and Abbott Laboratories ABT.N has been knocked back by U.S. regulators, who are seeking more information about the product.
The manufacturers said on Tuesday they had received a so-called “complete response letter” from the U.S. Food and Drug Administration for Certriad, which combines Astra’s blockbuster cholesterol pill Crestor and Abbott’s TriLipix.
Both companies said they were evaluating the letter from the agency and would respond to the request for additional information. An AstraZeneca spokesman declined to give further details.
Some analysts have voiced concerns about whether Certriad would pass muster with regulators after a clinical study earlier this month showed no additional benefit from adding a drug like TriLipix to a statin such as Crestor. [ID:nN14199420] (Reporting by Ben Hirschler; editing by Kate Holton)
Our Standards: The Thomson Reuters Trust Principles.